Skip to main content

Daxor Corp

DXR
Exchange
Nasdaq
SEC CIK
0000027367

No open-market purchases or sales by Daxor Corp insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.33M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Daxor Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Daxor Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Daxor Corp
NameTitleLast reported holdingLast filingFilings, past year
Jefferies JohnChief Medical Officer26,008Sep 1, 20263
Michel Robert JChief Financial Officer33,050Jun 25, 20263
Feldschuh Michael RichardChief Executive Officer243,694Jun 25, 20262
Feuer EdwardDirector1,000Jun 25, 20261
Feldschuh Jonathan AdamChief Scientific Officer78,908Jun 25, 20262
Cremisi Henry D.Director–Jun 25, 20261
Goudie Joy S.Director300Jun 25, 20261
DesRosiers CalebDirector3,157Jun 25, 20261
Estate of Joseph Feldschuh10% Owner2,549,455Sep 20, 20230
Lombard James ADirector–Jul 13, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 10, 2026 (view filing)Apr 82 daysFeldschuh Michael RichardChief Executive OfficerPPurchaseDaxor Common Stock+1.00K$9.07+$9.07K+0.5%213.7K after
Mar 31, 2026 (view filing)Mar 31Same dayMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+1.00K$9.90+$9.90K+5.0%21.1K after
Mar 24, 2026 (view filing)Mar 204 daysJefferies JohnChief Medical OfficerPPurchaseDaxor Common Stock+5.94K$0.00$0+33.7%23.6K after2 lots
Dec 11, 2025 (view filing)Dec 92 daysMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+3.00K$0.00$0+17.6%20.1K after
Dec 11, 2025 (view filing)Dec 92 daysFeldschuh Jonathan AdamChief Scientific OfficerPPurchaseDaxor Common Stock+18.0K$0.00$0+50.1%53.9K after
Nov 14, 2025 (view filing)Nov 122 daysJefferies JohnChief Medical OfficerPPurchaseDaxor Common Stock+2.34K$0.00$0+15.3%17.6K after
Apr 7, 2025 (view filing)Apr 43 daysFeldschuh Michael RichardChief Executive OfficerPPurchaseDaxor Common Stock+2.06K$7.89+$16.3K+1.0%212.7K after
Mar 27, 2025 (view filing)Mar 26, 2024366 daysLateFeldschuh Michael RichardChief Executive OfficePPurchaseDaxor Common Stock+1.00K$8.13+$8.13K+0.5%210.6K after
Mar 20, 2025 (view filing)Mar 10, 2024375 daysFeldschuh Michael RichardChief Executive OfficerPPurchaseDaxor Common Stock+1.49K$7.72+$11.5K+0.7%209.0K afterAmended
Mar 20, 2025 (view filing)Mar 19, 2024366 daysLateFeldschuh Michael RichardChief Executive OfficerPPurchaseDaxor Common Stock+647$8.15+$5.27K+0.3%209.6K after
Mar 11, 2025 (view filing)Mar 101 dayMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+1.00K$8.00+$8.00K+6.2%17.1K after
Dec 10, 2024 (view filing)Dec 64 daysFeldschuh Jonathan AdamChief Scientific OfficerPPurchaseDaxor Common Stock+32.0K$0.00$0+818.8%35.9K after
Dec 10, 2024 (view filing)Dec 64 daysFeldschuh Michael RichardChief Executive OfficerPPurchaseDaxor Common Stock+45.0K$0.00$0+27.7%207.5K after
Dec 10, 2024 (view filing)Mar 27, 2023624 daysLateMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+4.75K$0.00$0+46.1%15.1K after
Mar 27, 2024 (view filing)Mar 27Same dayMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+750$8.70+$6.53K+7.1%11.3K after
Mar 6, 2024 (view filing)Mar 42 daysFeuer EdwardDirectorPPurchaseDaxor Common Stock+1.00K$7.21+$7.21KNew position1.00K after
Dec 6, 2023 (view filing)Dec 6Same dayMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+120$7.75+$930+1.2%10.6K after
Dec 1, 2023 (view filing)Dec 1Same dayMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+180$7.75+$1.40K+1.8%10.4K after
Dec 1, 2023 (view filing)Dec 1Same dayFeldschuh Michael RichardChief Executive OfficerPPurchaseDaxor Common Stock+800$7.80+$6.24K+0.5%162.5K after
Nov 27, 2023 (view filing)Nov 243 daysMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+500$7.94+$3.97K+5.1%10.3K after
Nov 13, 2023 (view filing)Nov 9-104 daysFeldschuh Michael RichardCHIEF EXECUTIVE OFFICERPPurchaseDaxor Common Stock+1.40K$7.84+$11.0K+0.9%161.6K after2 lots
Oct 16, 2023 (view filing)Oct 133 daysMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+500$9.02+$4.51K+6.9%7.75K after
May 25, 2023 (view filing)May 241 dayFeldschuh Michael RichardCEO & PresidentPPurchase+2.00K$9.75+$19.5K+1.3%160.2K after
May 25, 2023 (view filing)May 241 dayGoudie Joy S.DirectorPPurchase+300$9.75+$2.92KNew position300 after
Nov 18, 2022 (view filing)Nov 171 dayDesRosiers CalebDirectorPPurchaseDaxor Common Stock+3.16K$9.50+$30.0KNew position3.16K after
Nov 18, 2022 (view filing)Nov 18Same dayMichel Robert JChief Financial OfficerPPurchaseDaxor Common Stock+1.00K$10.00+$10.0K+16.0%7.25K after